Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Viking Therapeutic (VKTX) PT Raised to $28 at SunTrust Robinson Humphrey
September 18, 2018 3:39 PM EDTSunTrust Robinson Humphrey analyst Edward Nash raised the price target on Viking Therapeutic (NASDAQ: VKTX) to $28.00 (from $14.00) while maintaining a Buy rating.
Nash commented, "Viking announced promising results from a Phase II study of VK2809 in NAFLD/hypercholesterolemia. 12-week treatment... More
Viking Therapeutic (VKTX) PT Raised to $28 at Maxim Group, Matching 'Street High'
September 18, 2018 12:31 PM EDTMaxim Group analyst Jason McCarthy raised the price target on Viking Therapeutic (NASDAQ: VKTX) to $28.00 (from $14.00) while maintaining a Buy rating. The new price target matches a Street High.
The analyst highlights:
VKTX shares are up sharply (~+80%) after announcing positive top-line 12-week P2 data for VK2809, an oral thyroid beta receptor agonist (TR), in Non-Alcoholic Fatty... MoreViking Therapeutic (VKTX) PT Raised to 'Street High' $28 at H.C. Wainwright
September 18, 2018 11:57 AM EDTH.C. Wainwright analyst Joseph Pantginis raised the price target on Viking Therapeutic (NASDAQ: VKTX) to a 'Street High' $28.00 (from $15.00) while maintaining a Buy rating.
The analsyt commented, "This morning, the highly anticipated VK2809 top-line data in non-alcoholic fatty liver disease (NAFLD) and... More
Viking Therapeutics (VKTX) Climbs 140% After Shares Resume Trading
September 18, 2018 7:37 AM EDTViking Therapeutics (NASDAQ: VKTX) Climbs 140% After Shares Resume Trading
... MoreViking Therapeutics (VKTX) to Resume Trading at 7:35 am ET
September 18, 2018 7:17 AM EDTViking Therapeutics (NASDAQ: VKTX) to Resume Trading at 7:35 am ET
... More